Evaluation of the combination of brentuximab vedotin and chemotherapy in peripheral CD30 + T lymphomas: controlled, randomized, double-blind trial

被引：0
|
作者：
Charlotte, Berthoux
Laure, Farnault
Geoffroy, Venton
机构：
来源：
HEMATOLOGIE | 2019年 / 25卷 / 02期
关键词：
D O I：
10.1684/hma.2019.1459
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：65 / 65
页数：1
相关论文
共 50 条
  • [1] Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
    Horwitz, Steven
    O'Connor, Owen A.
    Pro, Barbara
    Illidge, Tim
    Fanale, Michelle
    Advani, Ranjana
    Bartlett, Nancy L.
    Christensen, Jacob Haaber
    Morschhauser, Franck
    Domingo-Domenech, Eva
    Rossi, Giuseppe
    Kim, Won Seog
    Feldman, Tatyana
    Lennard, Anne
    Belada, David
    Illes, Arpad
    Tobinai, Kensei
    Tsukasaki, Kunihiro
    Yeh, Su-Peng
    Shustov, Andrei
    Huttmann, Andreas
    Savage, Kerry J.
    Yuen, Sam
    Iyer, Swaminathan
    Zinzani, Pier Luigi
    Hua, Zhaowei
    Little, Meredith
    Rao, Shangbang
    Woolery, Joseph
    Manley, Thomas
    Trumper, Lorenz
    Aboulafia, David
    Alpdogan, Onder
    Ando, Kiyoshi
    Arcaini, Luca
    Baldini, Luca
    Bellam, Naresh
    Bartlett, Nancy
    Ben Yehuda, Dina
    Benedetti, Fabio
    Borchman, Peter
    Bordessoule, Dominique
    Brice, Pauline
    Briones, Javier
    Caballero, Dolores
    Carella, Angelo Michele
    Chang, Hung
    Cheong, June Weon
    Cho, Seok-Goo
    Choi, Ilseung
    LANCET, 2019, 393 (10168): : 229 - 240
  • [2] The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas
    Horwitz, Steven M.
    O'Connor, Owen A.
    Pro, Barbara
    Illidge, Tim M.
    Fanale, Michelle A.
    Advani, Ranjana H.
    Bartlett, Nancy L.
    Christensen, Jacob Haaber
    Morschhauser, Franck
    Domingo-Domenech, Eva
    Rossi, Giuseppe
    Kim, Won Seog
    Feldman, Tatyana A.
    Lennard, Anne
    Belada, David
    Illes, Arpad
    Tobinai, Kensei
    Tsukasaki, Kunihiro
    Yeh, Su-Peng
    Shustov, Andrei R.
    Huettmann, Andreas
    Savage, Kerry J.
    Yuen, Sam
    Zinzani, Pier Luigi
    Hua, Zhaowei
    Little, Meredith
    Rao, Shangbang
    Woolery, Joseph
    Manley, Thomas
    Truemper, Lorenz
    BLOOD, 2018, 132
  • [3] The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 8 - 10
  • [4] Management of ALCL and other CD30+peripheral T-cell lymphomas with a focus on Brentuximab vedotin
    Nizamuddin, Imran
    Galvez, Carlos
    Pro, Barbara
    SEMINARS IN HEMATOLOGY, 2021, 58 (02) : 85 - 94
  • [5] PERSISTENCE OF CD30 EXPRESSION IN CD30-POSITIVE LYMPHOMAS FOLLOWING TREATMENT WITH BRENTUXIMAB VEDOTIN (SGN-35)
    Chen, W.
    Nathwani, N.
    Forman, S.
    Popplewell, L.
    Krishnan, A.
    Gomez, C.
    Karanes, C.
    Smith, E.
    Farol, L.
    Thomas, S.
    Kim, Y.
    HAEMATOLOGICA, 2012, 97 : 81 - 82
  • [6] Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (vol 393, pg 229, 2019)
    Horwitz, S.
    O'Connor, O. A.
    Pro, B.
    LANCET, 2019, 393 (10168): : 228 - 228
  • [7] CD30 expression in peripheral T-cell lymphomas
    Sabattini, Elena
    Pizzi, Marco
    Tabanelli, Valentina
    Baldin, Pamela
    Sacchetti, Carlo Sagramoso
    Agostinelli, Claudio
    Zinzani, Pier Luigi
    Pileri, Stefano A.
    HAEMATOLOGICA, 2013, 98 (08) : E81 - E82
  • [8] Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma
    Gentille, Cesar
    Sarfraz, Humaira
    Joshi, Jitesh
    Randhawa, Jasleen
    Shah, Shilpan
    Pingali, Sai Ravi
    CANCER REPORTS, 2022, 5 (07)
  • [9] Epigenetically induced expression of CD30 in T-PLL: A rationale for the use of brentuximab vedotin
    Hasanali, Zainul
    Sharma, Kamal
    Shimko, Sara
    Stuart, August
    Liu, Xin
    Epner, Elliot E.
    Loughran, Thomas P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Phase II Trial Of Brentuximab Vedotin For CD30+Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders
    Duvic, Madeleine
    Tetzlaff, Michael
    Clos, Audra L.
    Gangar, Pamela
    Talpur, Rakhshandra
    BLOOD, 2013, 122 (21)
12345